AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17047001
Drug: T‐‐>EC (T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T‐‐>EC (T 100 mg/m2 x 4, then E 100 mg/m2, C 600 mg/m2 x 4) every 2 weeks
Trial: 2227588
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 every 28 days
Trial: 2227588
Drug: Carboplatin 400
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 400 mg/m2 every 28 days
Trial: 2227588
Drug: Cisplatin second-line
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin second-line treatment
Trial: 2227588
Drug: Carboplatin second-line
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin second-line treatment
Trial: 24170763
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin lispro (insulin lispro mix 25 and/or insulin lispro mix 50)
Trial: 24170763
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin glargine plus up to three injections of insulin lispro
Trial: 12913774
Drug: Dexamethasone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.6 mg/kg/day in four doses for 48 h)
Trial: 8536777
Drug: DMPA 150
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA 150 mg single-dose intramuscular injection
Trial: 1780418
Drug: 2DG (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2DG (50 mg/kg)
Trial: 24149401
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TA) - 1 g starting 2 hours before surgery, 3 g daily in divided doses (1 g every 8 hours) for 5 days
Trial: 24149401
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone - single dose of 1 mg/kg at the beginning of surgery
Trial: 24343761
Drug: E2212 (10-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2212 (10-250 mg, single ascending oral doses)
Trial: 24343761
Drug: E2212 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2212 (250 mg cohort)
Trial: 19237833
Drug: H(2) receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H(2) receptor antagonists (H(2)RA)
Trial: 15203796
Drug: Venlafaxine (antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (antidepressant medication) plus standard care (brief counseling and nicotine replacement therapy)
Trial: 15203796
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard care (brief counseling and nicotine replacement therapy)
Trial: 8040679
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HD-MTX) treatment (900 to 3,700 mg/m2 intravenously over 24 hours)
Trial: 2923290
Drug: Caudal injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 10 mg in 1 mL INTRACAUDAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal injection of preservative-free morphine sulfate (0.075 mg/kg) in preservative-free normal saline (5-10 ml)
Trial: 4914612
Drug: Phenformin 100mg
RxNorm normalized name: phenformin
DrugBank: Phenformin (DB00914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenformin 100mg daily for six weeks
Trial: 4914612
Drug: Inert capsules
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert capsules for six weeks
Trial: 28662983
Drug: Adipose tissue-derived
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose tissue-derived mesenchymal stromal cells (AT-MSCs) at a dosage of 1×10^6/kg (group A, n=9) or 3×10^6/kg (group B, n=5) with cyclosporine and prednisone as first-line therapy
Trial: 23261916
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy group
Trial: 10475716
Drug: Buspirone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5 mg, p.o.)
Trial: 10475716
Drug: Diazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (2 mg, p.o.)
Trial: 10475716
Drug: Fluvoxamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (25 mg, p.o.)
Trial: 1387866
Drug: Vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine plus HBIG
Trial: 6149939
Drug: bisoprolol 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol 20 mg
Trial: 6149939
Drug: terbutaline up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline up to 3.5 mg
Trial: 30424482
Drug: New Zealand
RxNorm normalized name: NEW ZEALAND GREEN MUSSEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Zealand blackcurrant extract (NZBC) - 600 mg total (two capsules of 300 mg each containing 35% blackcurrant extract)
Trial: 25233157
Drug: Reamed nail
RxNorm normalized name: FUNGI NAIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reamed nail treatment
Trial: 22714001
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg daclatasvir
Trial: 22714001
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg daclatasvir
Trial: 22714001
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg daclatasvir
Trial: 17312304
Drug: Tamoxifen (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (during active treatment)
Trial: 17312304
Drug: Tamoxifen (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (after treatment)
Trial: 12716266
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Fluoxetine or Nortriptyline)
Trial: 27110603
Drug: Apically positioned
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apically positioned flap with buccal approach (APF-B)
Trial: 27110603
Drug: Apically positioned
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apically positioned flap with buccal and palatal approach (APF-BP)
Trial: 21031576
Drug: Transdermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapy with a mixture of 3 myelin peptides: MBP85-99, PLP139-151, and MOG35-55
Trial: 19007923
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) for BN
Trial: 15994746
Drug: Fixed-dose GH
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose GH treatment
Trial: 8699994
Drug: Intravenous ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ATP at 50 micrograms/kg/minute
Trial: 8699994
Drug: Intravenous ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ATP at 75 micrograms/kg/minute
Trial: 8699994
Drug: Intravenous ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ATP at 100 micrograms/kg/minute
Trial: 8699994
Drug: Intravenous ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ATP (all doses)
Trial: 1928853
Drug: T3 and
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T3 and hydrocortisone (100 mg hydrocortisone intravenously, 2 or 4 micrograms T3 every hour or half hour)
Trial: 30743314
Drug: Voxelotor 900
RxNorm normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Voxelotor 900 mg for 15 days
Trial: 30743314
Drug: Voxelotor (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxelotor (various doses: 100, 400, 1000, 2000, or 2800 mg) single dose
Trial: 30743314
Drug: Voxelotor (300,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxelotor (300, 600, or 900 mg) multiple doses for 15 days
Trial: 30743314
Drug: Voxelotor in
RxNorm normalized name: Product containing voxelotor in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxelotor in SCD patients (1000 mg)
Trial: 30743314
Drug: Voxelotor (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxelotor (various doses)
Trial: 11748776
Drug: Citalopram augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram augmentation (20-40 mg/day)
Trial: 11748776
Drug: No citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No citalopram augmentation
Trial: 3717618
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with 2 mg phenylephrine
Trial: 3717618
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with 5 mg phenylephrine
Trial: 27905884
Drug: Pivmecillinam 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 400 mg t.i.d. for 3 days
Trial: 27905884
Drug: Pivmecillinam 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 400 mg b.i.d. for 5 days
Trial: 25286026
Drug: Placebo (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice-daily placebo)
Trial: 19001772
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d XOS for 8 weeks
Trial: 12091259
Drug: Active nutritional
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active nutritional supplements (vitamins, minerals, essential fatty acids)
Trial: 9527094
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide infusion
Trial: 7867113
Drug: Group C‐‐subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C‐‐subcutaneous ring block
Trial: 7867113
Drug: Group D‐‐a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D‐‐a combination of frenulum infiltration and the '10, 30‐13, 30' approach
Trial: 7867113
Drug: Group E‐‐a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group E‐‐a combination of frenulum infiltration and the subpubic approach
Trial: 7867113
Drug: Subcutaneous ring
RxNorm normalized name: RING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ring block or a combination of dorsal nerve block (using the '10, 30‐13, 30' or the subpubic approach) and infiltration of the frenulum
Trial: 2671200
Drug: Vinburnin (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinburnin (45 mg iv per day)
Trial: 991148
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (CA) synchronization plus vincristine, prednisone, and L-asparaginase
Trial: 23106186
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg.kg(‐1)
Trial: 23106186
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 μg.kg(‐1)
Trial: 19361897
Drug: Sodium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium intake <3 g/day (group 1)
Trial: 19361897
Drug: Sodium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium intake >6 g/day (group 2)
Trial: 15275792
Drug: Neurolytic sympathetic
RxNorm normalized name: Bos taurus sympathetic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurolytic sympathetic plexus block (NSPB) with alcohol in patients using NSAID and a weak oral opioid or morphine (dose ≤90 mg/day)
Trial: 15275792
Drug: Neurolytic sympathetic
RxNorm normalized name: Bos taurus sympathetic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurolytic sympathetic plexus block (NSPB) with alcohol in patients using NSAID and morphine (dose ≥90 mg/day)
Trial: 15275792
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy only (Control group)
Trial: 9070471
Drug: Ibuprofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (10 mg per kilogram of body weight, max 800 mg, given every six hours for eight doses)
Trial: 8363997
Drug: tropisetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6)
Trial: 31844890
Drug: VB-111 1013
RxNorm normalized name: VB-201
DrugBank: VB-201 (DB15259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VB-111 1013 viral particles every 8 weeks in combination with bevacizumab 10 mg/kg every 2 weeks
Trial: 31844890
Drug: VB-111 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VB-111 and bevacizumab combination
Trial: 28258773
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg administered 1 hour before surgery
Trial: 19842230
Drug: Concurrent neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent neoadjuvant chemoradiotherapy
Trial: 19842230
Drug: Sequential neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential neoadjuvant chemoradiotherapy
Trial: 7923516
Drug: Atracurium 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.75 mg.kg‐1
Trial: 7923516
Drug: Atracurium 1
RxNorm normalized name: cisatracurium 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 1 mg.kg‐1
Trial: 7923516
Drug: Succinylcholine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.5 mg.kg‐1 (Control)
Trial: 3407900
Drug: Oral intubation
RxNorm normalized name: ADAPTER,INTUBATION CAREFUSION #1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intubation with a laryngoscope (Group A, n = 50)
Trial: 18251642
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy delivered for 20 minutes using a piezoelectric transducer for 10 sessions over 4 weeks.
Trial: 18251642
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ultrasound therapy)
Trial: 17034311
Drug: Salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 200 microg (metered dose inhaler)
Trial: 14605789
Drug: Microcrystalline chitosan
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline chitosan (MCC) 1.2 g twice daily
Trial: 14605789
Drug: Placebo 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1.2 g twice daily
Trial: 9232667
Drug: Dextromethorphan (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (30 mg single dose)
Trial: 2982694
Drug: Vegetable protein
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable protein diet supplemented with psyllium fiber (0.8 g/kg body wt, 1800 kcal/day)
Trial: 2982694
Drug: Meat protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat protein diet (0.8 g/kg body wt, approximately 1800 kcal/day) plus neomycin and laxatives
Trial: 27613912
Drug: Combined nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined nicotine replacement therapy (NRT) and behavioral counseling
Trial: 25033113
Drug: Group-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based cognitive processing therapy (CPT)
Trial: 17969818
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment (short‐acting insulin in each meal and medium‐acting insulin before going to bed)
Trial: 17969818
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin treatment (two doses: morning and evening)
Trial: 8272992
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (8 ml) infiltrated 5 min before incision
Trial: 2888424
Drug: Cetirizine 2
RxNorm normalized name: cetirizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 2 HCl 10 mg
Trial: 27899130
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (cephalexin)
Trial: 20845288
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin 40 µg
Trial: 20845288
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin 40 µg plus intramuscular tramadol 100 mg
Trial: 12648180
Drug: 150 micro
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micro g Nestorone
Trial: 12648180
Drug: 200 micro
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micro g Nestorone
Trial: 12648180
Drug: 400 micro
RxNorm normalized name: EM 2400 Micro Volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micro g Nestorone
Trial: 11063500
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice a day from the day before to 3 days after mastectomy
Trial: 8931784
Drug: Thalidomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100 mg by mouth, four times daily) for 12 weeks
Trial: 30852478
Drug: Alteplase intravenous
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase intravenous thrombolysis
Trial: 29378038
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g cashew nuts/day for 12 weeks
Trial: 22668876
Drug: PEG‐IFN α‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN α‐2a (180 μg weekly) ± ribavirin (1000‐1200 mg daily) for 48 weeks
Trial: 17506733
Drug: Midazolam-propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midazolam-propofol group (midazolam at 0.1 mg.kg(‐1) followed by propofol at 1.5 mg.kg(‐1))
Trial: 17506733
Drug: Propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol group (propofol at 2.5 mg.kg(‐1))
Trial: 16163516
Drug: MDMA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (2 mg/kg, p.o.)
Trial: 10591433
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin (20-40 microg)
Trial: 2261147
Drug: Quinapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10 to 40 mg/day)
Trial: 6360297
Drug: Stamey-type bladder
RxNorm normalized name: Sus scrofa urinary bladder preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stamey-type bladder neck suspension
Trial: 30409409
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate infusion (500mg.day‐1 for 21 days)
Trial: 30409409
Drug: Milrinone infusion
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone infusion (0.5μg.kg‐1.min‐1 for 21 days)
Trial: 29509598
Drug: Vaginal estradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estradiol in softgel capsules
Trial: 25095322
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg/kg (M1)
Trial: 25095322
Drug: Ketamine 5
RxNorm normalized name: ketamine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 5 mg/kg (K1)
Trial: 22257365
Drug: SRA+G (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRA+G (Standard Risk Assessment with Genetic Testing)
Trial: 22257365
Drug: All arms
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All arms (SRA+G, SRA, No-test)
Trial: 14520944
Drug: Amoxicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1 g/day) and clarithromycin (0.5 g/day) for 10 days along with omeprazole (40 mg/day)
Trial: 14520944
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg/day) only
Trial: 8799523
Drug: bretazenil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bretazenil (0.5 mg) + alcohol
Trial: 8799523
Drug: diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam (10 mg) + alcohol
Trial: 8799523
Drug: bretazenil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bretazenil (0.5 mg)
Trial: 6723769
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cimetidine with 11 g aluminium phosphate
Trial: 6723769
Drug: Prednisolone with
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone with 11 g aluminium phosphate